PRESS RELEASE


GENFIT: Half-Year Report of Liquidity Contract with Crédit
Industriel et Commercial

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 8, 2025 -
GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the
lives of patients with rare and life-threatening liver diseases, today announced the half-year report
of the liquidity contract with Crédit Industriel et Commercial.


Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following
resources appeared on the liquidity account as of June 30, 2025:

• 201,100 shares
• €398 484.67

During the first half of 2025, total trading was:

• On the buy side: 1 412,901 shares for a total amount of €5,016,550.43
• On the sell side: 1 419,301 shares for a total amount of €5,061,074.96

During this same period, the number of trades were:

• On the buy side: 2,673
• On the sell side: 1,894

As a reminder, upon signing of the contract, the following resources appeared on the liquidity
account:

• 27, 911 shares
• €769 849,43



ABOUT GENFIT


GENFIT is a biopharmaceutical company committed to improving the lives of patients with rare,
life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in
liver disease research and development with a rich history and a solid scientific heritage spanning
more than two decades. Today, GENFIT has built up a diversified and rapidly expanding R&D
portfolio of programs at various stages of development. The Company focuses on Acute-on-
Chronic Liver Failure (ACLF). Its ACLF franchise includes five assets under development: VS-01,
G1090N, SRT-015, CLM-022 and VS-02-HE, based on complementary mechanisms of action using



GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com 1
PRESS RELEASE


different routes of administration. Other assets target other serious diseases, such as
cholangiocarcinoma (CCA), urea cycle disorder (UCD) and organic acidemia (OA). GENFIT's
expertise in the development of high-potential molecules from early to advanced stages, and in
pre-commercialization, was demonstrated in the accelerated approval of Iqirvo® (elafibranor1) by
the U.S. Food and Drug Administration, the European Medicines Agency and the Medicines and
Healthcare Regulatory Agency in the UK for Primary Biliary Cholangitis (PBC). Beyond therapies,
GENFIT also has a diagnostic franchise including NIS2+® in Metabolic dysfunction-associated
steatohepatitis (MASH, formerly known as NASH for non-alcoholic steatohepatitis) and TS-01
focusing on blood ammonia levels. GENFIT is headquartered in Lille, France and has offices in Paris
(France), Zurich (Switzerland) and Cambridge, MA (USA). The Company is listed on the Nasdaq
Global Select Market and on the Euronext regulated market in Paris, Compartment B (Nasdaq and
Euronext: GNFT). In 2021, Ipsen became one of GENFIT's largest shareholders, acquiring an 8%
stake in the Company's capital. www.genfit.com




FORWARD LOOKING STATEMENTS


This press release contains certain forward-looking statements, including those within the meaning
of the Private Securities Litigation Reform Act of 1995, in relation to GENFIT’s research and
development programs. The use of certain words, such as "believe", "potential", "expect", “target”,
“may”, “will”, "should", "could", "if" and similar expressions, is intended to identify forward-looking
statements. Although the Company believes its expectations are based on the current expectations
and reasonable assumptions of the Company’s management, these forward-looking statements
are subject to numerous known and unknown risks and uncertainties, which could cause actual
results to differ materially from those expressed in, or implied or projected by, the forward-looking
statements. These risks and uncertainties include, among others, the uncertainties inherent in
research and development, including in relation to safety of drug candidates, cost of, progression
of, and results from, our ongoing and planned clinical trials, patient recruitment, review and
approvals by regulatory authorities in the United States, Europe and worldwide, of our drug and
diagnostic candidates, pricing, approval and commercial success of elafibranor in the relevant
jurisdictions, exchange rate fluctuations, and our continued ability to raise capital to fund our
development, as well as those risks and uncertainties discussed or identified in the Company’s
public filings with the AMF, including those listed in Chapter 2 "Risk Factors and Internal Control"
of the Company's 2024 Universal Registration Document filed on April 29, 2025 (no. 25-0331) with
the Autorité des marchés financiers ("AMF"), which is available on GENFIT's website (www.genfit.fr)


1
Elafibranor is marketed and commercialized in the U.S by Ipsen under the trademark Iqirvo®.



GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com 2
PRESS RELEASE


and the AMF's website (www.amf.org), and those discussed in the public documents and reports
filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company’s 2024
Annual Report on Form 20-F filed with the SEC on April 29, 2025 and subsequent filings and reports
filed with the AMF or SEC or otherwise made public, by the Company. In addition, even if the results,
performance, financial position and liquidity of the Company and the development of the industry
in which it operates are consistent with such forward-looking statements, they may not be
predictive of results or developments in future periods. These forward-looking statements speak
only as of the date of publication of this press release. Other than as required by applicable law,
the Company does not undertake any obligation to update or revise any forward-looking
information or statements, whether as a result of new information, future events or otherwise.


CONTACTS

GENFIT | Investors

Tel: +33 3 2016 4000 | investors@genfit.com

GENFIT | Media

Stephanie Boyer – Press relations | Tel: +333 2016 4000 | stephanie.boyer@genfit.com




GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com 3
PRESS RELEASE


APPENDIX
H1 2025



Buy side Sell-side
Number Number
of Number of Traded amounts in of Number of Traded amounts in
Date
executio shares EUR executio shares EUR
ns ns
TOTAL 2 673 1 412 901 5 016 550,43 1 894 1 419 301 5 061 074,96
02/01/20
18 7501 39 31501
25 26 676,03 113 126,08
03/01/20
28 13001 14 8721
25 46 608,72 31 259,29
06/01/20
28 8001 12 8281
25 28 811,12 29 928,03
07/01/20
32 10501 10 3641
25 37 433,65 13 184,02
08/01/20
31 10001 16 5692
25 34 888,59 19 853,18
09/01/20
16 6387 20 14056
25 22 067,79 48 956,91
10/01/20
38 11458 12 6458
25 39 749,52 22 766,00
13/01/20
23 14422 6 2369
25 48 540,41 7 888,86
14/01/20
26 11900 7 6554
25 39 655,32 22 253,58
15/01/20
8 4170 15 8427
25 13 775,47 27 959,44
16/01/20
19 10283 12 11643
25 34 367,84 39 169,03
17/01/20
8 4501 13 8901
25 15 048,33 29 892,85
20/01/20
17 11722 52 29101
25 39 283,70 100 887,06
21/01/20
28 12501 17 8504
25 43 013,57 29 278,93
22/01/20
8 7501 15 17501
25 25 863,45 60 478,56
23/01/20
5 3463 8 3463
25 11 780,02 11 947,35
24/01/20
67 20501 14 17501
25 70 508,47 61 078,49
27/01/20
25 9424 6 6001
25 32 139,80 20 598,43
28/01/20
7 4576 13 12424
25 15 741,49 43059,72
29/01/20
24 13501 31 32076
25 47 980,93 114 587,98
30/01/20
28 22901 41 22901
25 82 748,18 85 288,59




GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com 4
PRESS RELEASE


31/01/20
28 21001 12 11001
25 75 763,63 40393,69
03/02/20
25 8001 17 12001
25 28 283,05 42 550,99
04/02/20
6 4001 29 15129
25 14 288,61 54 635,81
05/02/20
5 4501 15 13873
25 16 463,67 51 378,93
06/02/20
2 1001 17 17501
25 3 803,82 66 758,79
07/02/20
18 21001 4 1001
25 79 008,91 3 823,82
10/02/20
6 2001 15 11001
25 7 523,76 41 883,78
11/02/20
28 9001 6 9001
25 33 713,79 33 978,78
12/02/20
18 10001 14 20001
25 37 563,76 75 983,80
13/02/20
18 8001 16 9001
25 30 922,58 35 273,93
14/02/20
46 15533 10 6033
25 60 444,34 23 614,01
17/02/20
46 29501 21 13001
25 112 158,97 51 038,94
18/02/20
15 5001 1 1
25 18 853,77 3,76
19/02/20
44 22501 1 1
25 83 673,79 3,77
20/02/20
24 11501 4 4001
25 42 095,16 14 793,66
21/02/20
17 6001 8 9001
25 22 233,64 33 653,66
24/02/20
28 12626 11 5126
25 46 526,18 19 162,47
25/02/20
27 14501 3 1501
25 52 156,47 5 448,66
26/02/20
40 12501 3 1501
25 44 135,28 5 418,58
27/02/20
34 13501 9 3001
25 47 095,94 10 593,50
28/02/20
18 8001 14 8001
25 27 670,98 27 908,45
03/03/20
17 7927 6 4501
25 27 618,14 15 858,51
04/03/20
56 27575 1 1
25 93 607,75 3,48
05/03/20
12 5001 8 6001
25 16 953,39 20 583,37
06/03/20
14 6001 17 12501
25 20 526,54 43 158,45
07/03/20
19 9501 9 12001
25 32 680,49 41 523,46
10/03/20
22 10390 6 2390
25 35 334,10 8 302,19
11/03/20
30 17873 12 7612
25 60 362,84 26 437,16




GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com 5
PRESS RELEASE


12/03/20
18 6018 14 9262
25 20 285,59 31 572,49
13/03/20
19 12974 14 10491
25 43 533,09 35 670,87
14/03/20
14 11501 9 11658
25 38 110,86 38 789,55
17/03/20
8 4501 13 12344
25 14 938,32 41 027,14
18/03/20
6 2001 6 12001
25 6 743,35 40 660,83
19/03/20
5 4833 9 4833
25 16 153,92 16 270,05
20/03/20
16 6395 8 2895
25 21 319,84 9 704,68
21/03/20
21 11715 24 23001
25 39 002,28 78 600,86
24/03/20
20 9001 10 9443
25 30 091,96 31 887,41
25/03/20
17 15731 12 7002
25 52 698,38 23 694,07
26/03/20
29 15500 6 7501
25 51 262,53 24 948,33
27/03/20
8 9001 22 27001
25 30 115,82 90 988,24
28/03/20
26 5999 21 13501
25 20 299,06 45 903,40
31/03/20
18 12003 14 7957
25 39 730,05 26 311,33
01/04/20
21 19430 24 17930
25 63 908,96 59 739,17
02/04/20
20 10501 1 1
25 34 210,79 3,30
03/04/20
11 3749 6 7102
25 12 143,01 23 247,76
04/04/20
55 26310 3 1501
25 82 970,69 4 833,27
07/04/20
24 13987 15 15287
25 38 875,47 46 151,91
08/04/20
10 6001 12 21701
25 18 798,13 69 003,97
09/04/20
22 19301 28 16655
25 59 190,18 49 241,01
10/04/20
23 18647 28 18147
25 54 485,97 57 876,23
11/04/20
12 6001 35 22147
25 17 762,96 65 890,65
14/04/20
1 1 14 21501
25 3,03 66 128,05
15/04/20
8 3501 8 14501
25 10 903,09 45 608,11
16/04/20
7 4013 8 4013
25 12 515,42 12 565,75
17/04/20
31 14001 2 1501
25 43 387,14 4 659,13
22/04/20
16 8501 19 13501
25 26 059,05 41 697,03




GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com 6
PRESS RELEASE


23/04/20
9 9501 22 29501
25 29 894,04 92 551,13
24/04/20
21 12501 10 9001
25 39 929,82 29 004,19
25/04/20
19 9001 22 11001
25 29 006,26 35889,22
28/04/20
15 6501 17 13501
25 21 538,27 45075,25
29/04/20
12 9001 26 23984
25 31 239,41 83 723,35
30/04/20
26 24000 16 17927
25 85776,96 64 250,73
02/05/20
24 15388 38 23913
25 56 850,50 88 319,08
05/05/20
2 1501 28 25237
25 5988,79 101352,55
06/05/20
17 10501 35 28830
25 41 674,06 115 996,35
07/05/20
15 10001 6 2501
25 39 741,07 9 979,12
08/05/20
42 14950 10 4501
25 58602,65 17 715,98
09/05/20
37 22103 15 15052
25 87 132,24 60 102,03
12/05/20
21 13501 19 13501
25 51 579,90 52 404,94
13/05/20
22 12001 3 2001
25 46 129,92 7 739,89
14/05/20
8 6001 37 29501
25 22 746,85 112 696,77
15/05/20
42 23501 8 5001
25 86 604,48 18 724,74
16/05/20
27 12001 28 18001
25 44 615,52 67 124,65
19/05/20
33 25063 15 10584
25 93167,19 39 789,38
20/05/20
1 1 25 23480
25 3,71 89 983,81
21/05/20
9 7312 44 32312
25 29347,96 130 858,75
22/05/20
16 8001 24 12001
25 32 218,83 48 707,02
23/05/20
51 44001 1 1
25 172 316,72 4,05
26/05/20
17 12002 11 6001
25 46 390,73 23 361,89
27/05/20
22 12411 6 3412
25 47 978,20 13 358,83
28/05/20
23 10004 21 13001
25 38 375,34 50 153,83
29/05/20
23 17000 29 29001
25 66 757,98 113 577,78
30/05/20
13 6501 32 17018
25 25744,94 67 628,17
02/06/20
21 11001 9 7001
25 43 788,05 27 830,03




GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com 7
PRESS RELEASE


03/06/20
11 9016 23 17501
25 35 775,94 69 705,08
04/06/20
23 15501 18 11001
25 60 720,98 43 470,01
05/06/20
32 25900 26 18300
25 100 374,41 71 216,65
06/06/20
46 17768 1 1
25 67 098,54 3,83
09/06/20
12 4010 20 11877
25 14 927,59 44 732,58
10/06/20
6 3115 22 10106
25 11 767,97 38 561,06
11/06/20
10 6992 17 7001
25 26 467,73 26 585,81
12/06/20
38 13001 6 3001
25 48 921,72 11 289,79
13/06/20
40 16740 14 7168
25 61 246,64 26 352,58
16/06/20
20 12001 9 5501
25 43 551,63 20 145,65
17/06/20
11 6439 17 11011
25 23 061,99 39 683,53
18/06/20
31 12001 4 3001
25 42 703,16 10 776,59
19/06/20
40 17001 4 3001
25 59 357,63 10 446,54
20/06/20
24 13501 7 6001
25 46 656,49 20 961,43
23/06/20
13 9001 30 21001
25 30 057,31 70 407,32
24/06/20
9 5001 3 2001
25 16 969,39 6 803,40
25/06/20
19 10001 10 4001
25 33 485,35 13 609,40
26/06/20
4 1001 35 19001
25 3 327,32 63 977,32
27/06/20
30 15530 14 9530
25 51 764,13 32 008,22
30/06/20
33 10851 10 6751
25 35 529,43 22 149,29




GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com 8